IN THE UNITED STATES PATENT AND TRADEMARK OFFICE DEC 2005

In	ra	ann	lica	tion	٥f٠

Borthwick, et al.

International App. No.:

PCT/EP2004/006591

Group Art Unit:

International Filing Date: June 17, 2004

Examiner:

For:

2-PYRROLIDONE DERIVATIVES AND USE THEREOF AS FACTOR XA

INHIBITORS

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the E

Exa	amine	r and officially made of record in accordance with the provisions of 37 CFR 1.97
	[] [X]	Copies of the references are enclosed Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d)) A copy of the International Search Report which issued on International Application No. PCT/EP2004/006591 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
A.	[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	OR []	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
B.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

IAP20 Rac'd PCT/PTO 19 DEC 2005

C.	[]	The Information Disclosure Statement transmitted herewith is being filed after a final action under 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.				
	In accordance with the requirements of 37 CFR 1.97(d):					
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.				
	[]	Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).				
	[]	The petition fee set forth in $\S 1.17(i)(1)$ (\$130.00) is submitted herewith.				
[X]	•	charge any required fees to Deposit Account No.07-1392. cate copy of this paper is attached.				

Respectfully Submitted,

Attorney for Appliant Registration No. 42,616

Date: 16 Dec. 2005

GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8911 Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					ATTORNEY DOCKET NO. PB60266USW		INDERNATION AD 5 APP.NO. PCT/EP2004/006591	
					APPLICANT			
					Borthwick et al	l .		
				INTERNATIONAL			GROUP	
					FILING DATE		0.100	
					6/17/04			
			U.S. P.	ATENT D	OCUMENTS			
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate
7GS/	1	6,034,093	3/7/00	Ewing et	al.			
11/	2	2002/183324	12/5/03	Jacobson et al.				
V	3	6,348,600	2/19/02	Ono et al.				
				ntinue on j				
			FOREIGN	N PATEN	T DOCUMENTS		···	
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes No
/GS/	4	03/053925	7/3/03	PCT				
98	5	98/24784	6/11/98	PCT				
99000	6	01/39759	6/7/01	PCT				
	7	03/043981	5/30/03	PCT	•			
90000	8	2002/002519	1/10/02	PCT				
	9	92/10476	6/25/92	PCT				
	10	97/43257	11/20/97	PCT				
	11	2002/080853	10/17/02	PCT				
*			Co	ntinue on j	oage			
	OI	THER DOCUME	ENTS (Includin	g Author,	Title, Journal-D	ate, Page Nu	mber, Etc.)	
			<u> </u>					
	ļ							
	1							
	—							
	-							
	ļ	ļ		• •				
	<u> </u>	 						
	<u> </u>	<u> </u>	~					
DVANDY	<u> </u>	(Calama Charas		ontinue on	page	DATE	CONCIDENT	<u> </u>
EXAMINE		/Golam Shameer					CONSIDERED	
					tation is in confor			